Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in serious adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children under 18 years of age with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults and children with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults and children with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with asthma
Mepolizumab intravenous (IV) leads to lower serious adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with asthma
Reslizumab intravenous (IV) showed no clear difference in serious adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with asthma
Reslizumab subcutaneous (SC) showed no clear difference in serious adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with asthma
Benralizumab subcutaneous (SC) leads to lower serious adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with asthma
Mepolizumab subcutaneous (SC) showed no clear difference in serious adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Serious adverse events · people with systemic sclerosis
1 finding from 1 review
Serious adverse events · people with systemic sclerosis
Autologous non‐myeloablative selective HSCT probably leads to higher serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Serious adverse events · people with substance use disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with substance use disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found